Lexeo Therapeutics, Inc. Common Stock (LXEO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
345 Park Avenue South
New York City, NY 10010
United States of America (the)
Phone
212-547-9879
Website
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
November 03, 2023
| Name | Title | Pay | Year Born |
| R. Nolan Townsend | Chief Executive Officer & Director | 991,470 | 1981 |
| Louis Tamayo | Chief Financial Officer & Principal Accounting Officer | 638,897 | 1977 |
| Eric Adler | Advisor | 2.71M | 1974 |
| Jose Manuel Otero | Chief Operating Officer | 2.99M | 1979 |
| Ashley Kaplowitz | Head of Capital Markets | 0 | N/A |
| Ronald G. Crystal | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | 0 | N/A |
| Keith Wonnacott | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Narinder Bhalla FACC FSCAI | Chief Medical Officer | 0 | 1964 |
| Leslie DiRisio | Senior Vice President of Development Operations | 0 | N/A |
| Ryan McHenry | Vice President & Corporate Controller | 0 | N/A |
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.